Advertisement
ALKS vs RDY
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALKS is a Buy and RDY is a Buy.
Momentum Indicator for ALKS turns positive, indicating new upward trend
ALKS saw its Momentum Indicator move above the 0 level on October 19, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 102 similar instances where the indicator turned positive. In 83 of the 102 cases, the stock moved higher in the following days. The odds of a move higher are at 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ALKS's RSI Indicator exited the oversold zone, 17 of 22 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
ALKS moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ALKS crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 74%.
Following a +1.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALKS advanced for three days, in 203 of 278 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 60 cases where ALKS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 75%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALKS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 65%.
ALKS broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ALKS entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 41 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. ALKS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 85 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.258) is normal, around the industry mean (6.379). ALKS has a moderately high P/E Ratio (114.750) as compared to the industry average of (0.548). ALKS's Projected Growth (PEG Ratio) (21.570) is very high in comparison to the industry average of (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (4.638) is also within normal values, averaging (183.387).
RDY's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for RDY turned positive on October 09, 2026. Looking at past instances where RDY's MACD turned positive, the stock continued to rise in 29 of 48 cases over the following month. The odds of a continued upward trend are 60%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on RDY as a result. In 46 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 55%.
Following a +3.58% 3-day Advance, the price is estimated to grow further. Considering data from situations where RDY advanced for three days, in 157 of 318 cases, the price rose further within the following month. The odds of a continued upward trend are 49%.
The Aroon Indicator entered an Uptrend today. In 85 of 243 cases where RDY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 35%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 20 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RDY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
RDY broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. RDY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.032) is normal, around the industry mean (6.379). P/E Ratio (0.375) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (1.666) is also within normal values, averaging (2.202). Dividend Yield (0.020) settles around the average of (0.062) among similar stocks. P/S Ratio (2.817) is also within normal values, averaging (183.387).
The Tickeron Profit vs. Risk Rating rating for this company is 60 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 73 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
ALKS | RDY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 39 | 38 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 100 Overvalued | 50 Fair valued | |
PROFIT vs RISK RATING 1..100 | 41 | 60 | |
SMR RATING 1..100 | 85 | 73 | |
PRICE GROWTH RATING 1..100 | 42 | 39 | |
P/E GROWTH RATING 1..100 | 2 | 97 | |
SEASONALITY SCORE 1..100 | n/a | 22 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RDY's Valuation (50) in the Pharmaceuticals Generic industry is somewhat better than the same rating for ALKS (100) in the Biotechnology industry. This means that RDY’s stock grew somewhat faster than ALKS’s over the last 12 months.
ALKS's Profit vs Risk Rating (41) in the Biotechnology industry is in the same range as RDY (60) in the Pharmaceuticals Generic industry. This means that ALKS’s stock grew similarly to RDY’s over the last 12 months.
RDY's SMR Rating (73) in the Pharmaceuticals Generic industry is in the same range as ALKS (85) in the Biotechnology industry. This means that RDY’s stock grew similarly to ALKS’s over the last 12 months.
RDY's Price Growth Rating (39) in the Pharmaceuticals Generic industry is in the same range as ALKS (42) in the Biotechnology industry. This means that RDY’s stock grew similarly to ALKS’s over the last 12 months.
ALKS's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for RDY (97) in the Pharmaceuticals Generic industry. This means that ALKS’s stock grew significantly faster than RDY’s over the last 12 months.
| ALKS | RDY | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 77% | 2 days ago 75% |
| Stochastic ODDS (%) | 2 days ago 75% | 2 days ago 55% |
| Momentum ODDS (%) | 2 days ago 81% | 2 days ago 55% |
| MACD ODDS (%) | N/A | 2 days ago 60% |
| TrendWeek ODDS (%) | 2 days ago 72% | 2 days ago 50% |
| TrendMonth ODDS (%) | 2 days ago 73% | 2 days ago 45% |
| Advances ODDS (%) | 2 days ago 73% | 3 days ago 49% |
| Declines ODDS (%) | 10 days ago 65% | 29 days ago 55% |
| BollingerBands ODDS (%) | 2 days ago 66% | 2 days ago 57% |
| Aroon ODDS (%) | 2 days ago 60% | 2 days ago 35% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALKS’s FA Score shows that 1 FA rating(s) are green while RDY’s FA Score has 0 green FA rating(s).
- ALKS’s FA Score: 1 green, 4 red.
- RDY’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALKS’s TA Score shows that 5 TA indicator(s) are bullish while RDY’s TA Score has 4 bullish TA indicator(s).
- ALKS’s TA Score: 5 bullish, 4 bearish.
- RDY’s TA Score: 4 bullish, 4 bearish.
Price Growth
ALKS (@Pharmaceuticals: Generic) experienced а +1.71% price change this week, while RDY (@Pharmaceuticals: Generic) price change was +3.92% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.20%. For the same industry, the average monthly price growth was -6.54%, and the average quarterly price growth was +10.31%.
Reported Earning Dates
ALKS is expected to report earnings on Feb 17, 2027.
RDY is expected to report earnings on Jan 22, 2027.
Industries' Descriptions
@Pharmaceuticals: Generic (-0.20% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
RDY and
Correlation & Price change
A.I.dvisor tells us that RDY and VTRS have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RDY and VTRS's prices will move in lockstep.
| Ticker / NAME | Correlation To RDY | 1D Price Change % | ||
|---|---|---|---|---|
| RDY | 100% | -1.26% | ||
| VTRS - RDY | 28% Poorly correlated | +1.76% | ||
| ALKS - RDY | 28% Poorly correlated | +0.65% | ||
| HROW - RDY | 26% Poorly correlated | +10.52% | ||
| DERM - RDY | 25% Poorly correlated | -2.21% | ||
| LFCR - RDY | 24% Poorly correlated | N/A | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| IONZ | 19.88 | 0.31 | +1.58% |
| Defiance Daily Target 2x Short IONQ ETF (IONZ) | |||
| CSRE | 29.07 | 0.01 | +0.03% |
| Cohen & Steers Real Estate Active ETF (CSRE) | |||
| MINN | 21.77 | -0.06 | -0.29% |
| Mairs & Power Minnesota Municipal Bond ETF (MINN) | |||
| DFCF | 40.82 | -0.31 | -0.75% |
| Dimensional Core Fixed Income ETF (DFCF) | |||
| PGRO | 44.46 | -0.34 | -0.76% |
| Putnam Focused Large Cap Growth ETF (PGRO) | |||